We read the article by McGill and Ambrose on lupus in young people with interest.1 They reiterate that patients should receive retinal screening after 5 years of exposure to hydroxychloroquine.1 It is estimated that there may be up to 161 000 users of hydroxychloroquine in the UK. The prevalence of hydroxychloroquine retinopathy is around 7.5% after 5 years of hydroxychloroquine therapy (increasing to 20–50% after 20 years).2 The Royal College of Ophthalmologists has made a collaborative recommendation for systematic retinal screening in users of hydroxychloroquine and chloroquine in the UK.3 GPs and other prescribers of hydroxychloroquine, who take responsibility for drug monitoring requirements, should be aware of the key details of the recommendations:
all patients expected to remain on hydroxychloroquine for more than 5 years should be referred to the hospital eye service for baseline evaluation within 12 months of starting treatment;3
patients should be referred to the hospital eye service for annual screening after 5 years of treatment;
patients with additional risk factors (chloroquine use, impaired renal function (eGFR <50 ml/min/1.73 m2), daily dose of hydroxychloroquine greater than 5 mg/kg/day, and patients concurrently taking tamoxifen)4 should be screened annually after 1 year of treatment; and
prescribers should note that the risk of retinal toxicity can be reduced by ensuring the daily dose of hydroxychloroquine is <5 mg/kg/day.
A patient information leaflet has been developed by the Macular Society and should be distributed to all patients taking hydroxychloroquine.4 A referral form is included with the recommendations to assist in the timely referral of patients to the hospital eye service for baseline evaluation and screening. The patient, GP, and hospital specialist (if relevant) will be notified in writing of the outcome of each screening visit.
- © British Journal of General Practice 2018